Article

Dr. Rosevear: Practicing in a pandemic

Author(s):

Benjamin P. Saylor

Henry Rosevear, MD, talks about how he and his practice are coping with the COVID-19 pandemic.

Henry Rosevear, MD, Urology Times® Clinical Practice Board member and blogger, has written thoughtfully and eloquently about the COVID-19 pandemic in recent blog posts for UrologyTimes.com. Urology Times® spoke to him on April 7 about how he and his practice are coping with the present situation.   Also see:   COVID-19 and urology: What you can do   How ‘elective’ surgery is defined during the COVID-19 crisis   Telemedicine in urology: A crash course during the COVID-19 pandemic

 

Related Videos
Illustration of prostate | Image Credit: © Judith - stock.adobe.com
Medcast series
Related Content
64Cu-SAR-bisPSMA shows efficacy in detection of biochemically recurrent prostate cancer
March 6th 2025

64Cu-SAR-bisPSMA shows efficacy in detection of biochemically recurrent prostate cancer

Hannah Clarke
The detection rate ranged from 44% to 58% on day 0 and 58% to 80% on day 1.
Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management
March 3rd 2025

Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
Trial of 64Cu/67Cu-SAR-bisPSMA in mCRPC progresses to dose expansion phase
March 5th 2025

Trial of 64Cu/67Cu-SAR-bisPSMA in mCRPC progresses to dose expansion phase

Hannah Clarke
The safety review committee recommended that the phase 2 portion proceed with the 8 GBq dose.
Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management
February 21st 2025

Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
FDA greenlights pivotal trial of Voro Urologic Scaffold for postprostatectomy SUI
March 4th 2025

FDA greenlights pivotal trial of Voro Urologic Scaffold for postprostatectomy SUI

Hannah Clarke
The ARID II trial is assessing the safety and effectiveness of the device in men who are scheduled to undergo robotic-assisted radical prostatectomy.
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
March 4th 2025

UTUC roundtables: Grade and location drive care

Urology Times staff
In 2 recent case-based roundtable discussions, experts tackled diagnosis and treatment strategy for upper tract urothelial carcinoma.
© 2025 MJH Life Sciences

All rights reserved.